Home

PARTERS VII L P DOMAIN

CIK 1374150 · last filed 2014-03-21

PARTERS VII L P DOMAIN is a corporate insider who has filed 20 SEC Form 4 insider transactions across 7 companies since 2008. Across all open-market trades the lifetime net is +$48.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $5.5M across reported positions. 42 SEC filings were submitted jointly with JAMES C BLAIR.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.46M

Companies

7

Total Filings

20

Lifetime Open-Market Net

$48.85M

Filer Profile

Reported Address
ONE PALMER SQUARE SUITE 515
PRINCETON, NJ 08542
Phone
(609) 683-5656
Related Filers
JAMES C BLAIR — 42 joint filings, latest 2019-08-08
BRIAN H DOVEY — 42 joint filings, latest 2019-08-08
Brian K Halak — 42 joint filings, latest 2019-08-08
JESSE I TREU — 42 joint filings, latest 2019-08-08
NICOLE VITULLO — 42 joint filings, latest 2019-08-08
KATHLEEN K SCHOEMAKER — 32 joint filings, latest 2015-08-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Achaogen, Inc. (AKAO) Delisted 10%+ Owner 1,987,049 — — $0 1 2014-03-17
TNDM 10%+ Owner 318,906 $17.11 $5.46M $0 1 2013-11-19
Evoke Pharma Inc (OMED) Delisted 10%+ Owner 1,114,327 — — $0 1 2013-09-30
Esperion Therapeutics, Inc. (ESPR) Delisted 10%+ Owner 1,786,012 $3.18 $5.68M $3.93M 1 2013-07-02
Orexigen Therapeutics, Inc. (OREX) Delisted 10%+ Owner 296,742 — — $16.89M 12 2011-12-22
Clovis Oncology, Inc. (CLVS) Delisted 10%+ Owner 1,704,080 $0.08 $138.4K $11.91M 1 2011-11-21
ZOGENIX, INC. (ZGNX) Delisted 10%+ Owner 1,240,417 $26.68 $33.09M $16.12M 2 2011-09-20

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2014-03-21 — Disp (D) −2,972,678 -$41.62M
2014-03-17 Achaogen, Inc. (AKAO) Delisted Conv (C) +1,987,049 $0 EDGAR
2013-11-19 TNDM Mixed +3,189,058 $0 EDGAR
2013-09-30 Evoke Pharma Inc (OMED) Delisted Conv (C) +1,114,327 $0 EDGAR
2013-07-02 Esperion Therapeutics, Inc. (ESPR) Delisted Mixed +2,066,935 $3.93M EDGAR
2011-12-22 Orexigen Therapeutics, Inc. (OREX) Delisted Buy (P) +461,265 $668.8K EDGAR
2011-11-21 Clovis Oncology, Inc. (CLVS) Delisted Mixed +2,990,937 $11.91M EDGAR
2011-09-20 ZOGENIX, INC. (ZGNX) Delisted Buy (P) +3,441,304 $6.88M EDGAR
2010-12-01 ZOGENIX, INC. (ZGNX) Delisted Mixed +6,482,031 $9.24M EDGAR
2009-12-21 Orexigen Therapeutics, Inc. (OREX) Delisted Buy (P) +135,784 $1.02M EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.